Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma

8. desember 2020 oppdatert av: University of Washington

Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Men Undergoing Androgen Deprivation Therapy

This trial studies the mechanisms of metabolic and hormone action on plaque formation in brain and carotid vessels in patients with prostate adenocarcinoma. Studying the biomarkers in the laboratory may help doctors know the impact of androgen deprivation on metabolic, brain and cardiovascular endpoints.

Studieoversikt

Detaljert beskrivelse

OUTLINE:

Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.

Studietype

Observasjonsmessig

Registrering (Faktiske)

2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Washington
      • Seattle, Washington, Forente stater, 98109
        • Fred Hutch/University of Washington

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Mann

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Participants with prostate adenocarcinoma

Beskrivelse

Inclusion Criteria:

  • Signed informed consent
  • Histologically confirmed adenocarcinoma of the prostate
  • Non-castrate disease with a serum testosterone level >= 50 ng/dL (1.73 nmol/L) at baseline
  • No evidence of distant metastatic disease on baseline computed tomography-chest, abdomen and pelvis (CT-CAP) and bone scans
  • Patients will be stratified by the presence or absence of pre-existing cardiovascular disease defined as at least one of the following:

    • Prior myocardial infarction >= 30 days before enrollment
    • Prior revascularization procedure >= 30 days before consent, including:

      • Coronary artery stent placement or balloon angioplasty
      • Coronary artery bypass graft surgery
      • Stent placement or balloon angioplasty to a carotid, iliac, femoral, or popliteal artery
      • Carotid endarterectomy surgery
      • Vascular bypass surgery of the iliac, femoral, or popliteal artery
    • Results from angiogram or CT angiogram of coronary, carotic, iliac, femoral, or popliteal arteries that documents at least one vascular stenosis >= 50% at any time point before enrollment
    • Carotid ultrasound results that shows stenosis >= 50% at any time point before enrollment
    • Ankle-brachial pressure index < 0.9 at any time point before enrollment
  • Intent to initiate continuous androgen deprivation therapy (ADT) for at least 12 months

Exclusion Criteria:

  • No prior treatment with ADT at time of study entry. (Prior neoadjuvant/adjuvant ADT is allowed only if the last injection of a depot formulation wore off at least 12 months prior to enrollment)
  • Previous or concurrent hormonal or systemic therapy for prostate cancer including: anti-androgens, estrogens, megestrol acetate, ketoconazole, abiraterone, enzalutamide, or chemotherapy. (Prior or planned neoadjuvant bicalutamide for prevention of tumor flare is allowed)
  • Plans to start or continue treatment with an investigational product after enrollment
  • Poorly controlled type 1 or type 2 diabetes mellitus, based on hemoglobin A1c, as judged by the investigator
  • Prior or planned surgical castration
  • Poorly controlled hypertension at time of study entry, as judged by the investigator
  • Myocardial infarction or stroke < 30 days prior to enrollment
  • Coronary, carotid, or peripheral artery revascularization < 30 days prior to enrollment
  • Planned or scheduled cardiac surgery or percutaneous coronary intervention (PCI) procedure that is known at the time of enrollment
  • Mental incapacity or language barrier precluding adequate understanding or cooperation
  • Inability to tolerate magnetic resonance imaging (MRI) imaging, or both Lupron and Degarelix
  • Any other clinically significant disorder which may affect the subject's health or the outcome of the trial as judged by the investigator
  • Estimated glomerular filtration rate (eGFR) < 45
  • History of allergy to gadolinium contrast agent

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Clinical Evaluations
Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
Hjelpestudier
Undergo clinical evaluations

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in visual characterization of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results after Andorgen Deprivation Therapy
Tidsramme: 12 Months
Change From Baseline visual characterization scan results at 12 months
12 Months
Change standardized uptake values of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results
Tidsramme: 12 Months
Change from baseline standardized uptake values in select regions of interest at 12 months
12 Months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cognitive test results: Story recall
Tidsramme: 12 months
Change in baseline Story Recall results at 12 months
12 months
Cognitive Test Results: Change in Montreal Cognitive Assessment (MOCA)
Tidsramme: 12 Months
Change in baseline MOCA score results at 12 months
12 Months
Cognitive Test Results: Change in Clinical Dementia Rating Scale
Tidsramme: 12 Months
Change in baseline Clinical Dementia Rating Scale score at 12 months
12 Months
Cognitive Test Results: Digit span
Tidsramme: 12 Months
Change in baseline Digit span results at 12 months
12 Months
Cognitive Test Results: Letter number sequencing
Tidsramme: 12 Months
Change in baseline Letter number sequencing results at 12 months
12 Months
Cognitive Test Results: Stroop Test Results
Tidsramme: 12 Months
Change in baseline Stroop Test Results at 12 months
12 Months
Cognitive Test Results: Symbol Digit Modalities Test
Tidsramme: 12 Months
Change in baseline Symbol Digit Modalities Test score at 12 months
12 Months
Cognitive Test Results: Visuo-Spatial Learning Test
Tidsramme: 12 Months
Change in baseline Visuo-Spatial Learning Test results at 12 months
12 Months
Cognitive Test Results: Rey auditory verbal learning test (RVLT)
Tidsramme: 12 Months
Change in baseline Rey auditory verbal learning test (RVLT) score at 12 months
12 Months
Inflammatory and immune markers: Change in CRP
Tidsramme: 12 Months
Change in baseline CRP values at 12 months
12 Months
Inflammatory and immune markers: Change in IGFBP3
Tidsramme: 12 Months
Change in baseline IGFBP3 at 12 months
12 Months
Inflammatory and immune markers: Change in IGFBP1
Tidsramme: 12 Months
Change in baseline IGFBP1 at 12 months
12 Months
Inflammatory and immune markers: Change in IGF-1
Tidsramme: 12 Months
Change in baseline IGF-1 at 12 months
12 Months
Inflammatory and immune markers: Change in IL-6
Tidsramme: 12 Months
Change in baseline IL-6 at 12 months
12 Months
Metabolic Markers: Change in HgbA1C
Tidsramme: 12 Months
Change in baseline HgbA1C at 12 months
12 Months
Metabolic Markers: Change in Estradiol
Tidsramme: 12 Months
Change in baseline Estradiol at 12 months
12 Months
Metabolic Markers: Change in Follicle Stimulating Hormone (FSH)
Tidsramme: 12 Months
Change in baseline Change in Follicle Stimulating Hormone (FSH) at 12 months
12 Months
Metabolic Markers: Change in Leptin
Tidsramme: 12 Months
Change in baseline Leptin at 12 months
12 Months
Metabolic Markers: Change in Adiponectin
Tidsramme: 12 Months
Change in baseline Adiponectin at 12 months
12 Months
Metabolic Markers: Change in homeostatic model assessment of insulin resistance (HOMA-IR)
Tidsramme: 12 Months
Change in baseline HOMA-IR values at 12 months; Calculated based on fasting glucose and insulin test results.
12 Months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Evan Yu, Fred Hutch/University of Washington Cancer Consortium

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. oktober 2019

Primær fullføring (Faktiske)

12. mars 2020

Studiet fullført (Faktiske)

12. mars 2020

Datoer for studieregistrering

Først innsendt

12. september 2018

Først innsendt som oppfylte QC-kriteriene

22. oktober 2018

Først lagt ut (Faktiske)

24. oktober 2018

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. desember 2020

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. desember 2020

Sist bekreftet

1. desember 2020

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • RG1001903
  • 9939 (FHCRC)
  • NCI-2018-01618 (Registeridentifikator: CTRP)
  • 5P30CA015704 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere